CA4236943060
© Newsfile
06.01.2025
HEM
LISTED
TSX
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash
News Preview
Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has incorporated Hemostemix PR Inc., in Puerto Rico, as a wholly owned subsidiary and a domestic for profit corporation.Under Puerto Rico's ACT 60 program, Hemostemix PR Inc. is eligi...
Themefolio
Profiler
Peergroup
© Newsfile
02.01.2025
HEM
LISTED
TSX
Hemostemix is Up-Listing in the USA to Generate Liquidity
News Preview
Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its shares on the OTCQB Venture Market. Currently listed on the TSXV Exchange, Frankfurt, and the OTC, Hemostemix aims to increase its liquidity by...
Themefolio
Profiler
Peergroup
© Newsfile
31.12.2024
HEM
LISTED
TSX
Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction
News Preview
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating individuals about treatments and advancements.Calgary, Alberta--(Newsfile Corp. - December 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to an...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
17.12.2024
HEM
LISTED
TSX
Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments
News Preview
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating about its treatments and advancements.Calgary, Alberta--(Newsfile Corp. - December 17, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
03.12.2024
HEM
LISTED
TSX
Hemostemix Announces $2,725,982 Update to Second Closing
News Preview
Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is amending its closing documents to include an additional subscription of $50,000. The combined Offerings resulted in gross proceeds of $2,725,981.77 upon the issuance...
Themefolio
Profiler
Peergroup
© Newsfile
28.11.2024
HEM
LISTED
TSX
Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
News Preview
Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $833,258 (the "Offering")....
Themefolio
Profiler
Peergroup
© Newsfile
25.11.2024
HEM
LISTED
TSX
Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway
News Preview
Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals suffering from Chronic Limb Threatening Ischemia ("CLTI"), Angin...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2024
HEM
LISTED
TSX
Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted o...
Themefolio
Profiler
Peergroup
© Newsfile
11.10.2024
HEM
LISTED
TSX
Hemostemix's Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Sh...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2024
HEM
LISTED
TSX
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
News Preview
Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical...
Themefolio
Profiler
Peergroup
© Newsfile
11.06.2024
HEM
LISTED
TSX
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
News Preview
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI...
Themefolio
Profiler
Peergroup
© Newsfile
03.06.2024
HEM
LISTED
TSX
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
News Preview
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
07.03.2024
HEM
LISTED
TSX
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
News Preview
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Serv...
Themefolio
Profiler
Peergroup
© Newsfile
06.02.2024
HEM
LISTED
TSX
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
News Preview
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today.The publication highlights the results of no opti...
Themefolio
Profiler
Peergroup
© Newsfile
29.12.2023
HEM
LISTED
TSX
Hemostemix Clarifies its October 3, 2023 News Release
News Preview
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. The Company closed the financing in the amount of $320,385 with the issuance of 2,669,875...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2023
HEM
LISTED
TSX
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
News Preview
Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated card...
Themefolio
Profiler
Peergroup
© Newsfile
23.10.2023
HEM
LISTED
TSX
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
News Preview
Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 ("CD1") resulting in an expected interest saving of $569,868.The 4 material amendments are summarized as follows:...
Themefolio
Profiler
Peergroup
© Newsfile
03.10.2023
HEM
LISTED
TSX
Hemostemix Closed $320,125 Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit sold consisted of one common share in the capital of the Company ("Common Share") and one hal...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2023
HEM
LISTED
TSX
Hemostemix Announces Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall consist of one common share in the capital of the Company ("Common Share") and one half of on...
Themefolio
Profiler
Peergroup
© Newsfile
12.09.2023
HEM
LISTED
TSX
Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
News Preview
Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications of Implantable Biosensors Supporting Brain Computer Inte...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2023
HEM
LISTED
TSX
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
News Preview
Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant funding of $6 Million, to locate production of ACP-01 in Montreal. "We are moving production of ACP-01 to Quebec, as have negotitated terms for a poss...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2023
HEM
LISTED
TSX
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
News Preview
Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study to a leading stem cell journal. The study, Safety and Outcomes Analysis: Transcatheter Implantation of Autologous Angiogenic Cell Precursors for Tre...
Themefolio
Profiler
Peergroup
© Newsfile
28.06.2023
HEM
LISTED
TSX
Hemostemix Closes $403,539 of the Unit Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - June 28, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96. In connection with the Closing, the Corporation will pay finder fees ("Finder Fees") to one or more...
Themefolio
Profiler
Peergroup
© Newsfile
21.06.2023
HEM
LISTED
TSX
Hemostemix's Private Placement Use of Proceeds
News Preview
Calgary, Alberta--(Newsfile Corp. - June 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract in the form of a production facility cotenancy agreement negotiated by the Issuer, pay cur...
Themefolio
Profiler
Peergroup
© Newsfile
02.06.2023
HEM
LISTED
TSX
Hemostemix Announces Unit Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 10 Million Units priced at $0.12 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one half of one common sha...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2023
HEM
LISTED
TSX
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
News Preview
Calgary, Alberta--(Newsfile Corp. - May 2, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a company who is pursuing neural electrode-based brain intervention. Dr. McNorgan's research - the neural ba...
Themefolio
Profiler
Peergroup
© Newsfile
03.04.2023
HEM
LISTED
TSX
Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates
News Preview
Calgary, Alberta--(Newsfile Corp. - April 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business Development. The EVP Business Development will be respon...
Themefolio
Profiler
Peergroup
© Newsfile
29.03.2023
HEM
LISTED
TSX
Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
News Preview
Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia "CLI" and peripheral arterial disease "PAD" patients, global...
Themefolio
Profiler
Peergroup
© Newsfile
21.03.2023
HEM
LISTED
TSX
Hemostemix Closes $762,400 of The Unit Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering"). The Offering consisted...
Themefolio
Profiler
Peergroup
© Newsfile
08.03.2023
HEM
LISTED
TSX
Hemostemix Unit Offering Repriced
News Preview
Calgary, Alberta--(Newsfile Corp. - March 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its offering of 14 Million Common Share Units to $0.20 each. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full...
Themefolio
Profiler
Peergroup
© Newsfile
07.03.2023
HEM
LISTED
TSX
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
News Preview
Calgary, Alberta--(Newsfile Corp. - March 7, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unsecured convertible debentures ("CD") at USD $35,000 each. The CD can be converted into one of 500 ACP-01 therapeutic production slots ("TPS"), su...
Themefolio
Profiler
Peergroup
© Newsfile
02.02.2023
HEM
LISTED
TSX
Hemostemix Announces Unit Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - February 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 14 Million Units priced at $0.24 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purch...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2023
HEM
LISTED
TSX
The Force Family Office Engaged by Hemostemix
News Preview
Calgary, Alberta--(Newsfile Corp. - January 31, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is plugged into the largest network of family offices in the United States via its agreement with the Force Family Office. In 2022, The Force Family Office hosted more than 150 eve...
Themefolio
Profiler
Peergroup
© Newsfile
30.01.2023
HEM
LISTED
TSX
Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland
News Preview
Calgary, Alberta--(Newsfile Corp. - January 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its Trademark, Your Fountain of Youth, was granted protection in Switzerland by its Trademark Office. Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., has receive...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2023
HEM
LISTED
TSX
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
News Preview
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your Fountain o...
Themefolio
Profiler
Peergroup
© Newsfile
24.01.2023
HEM
LISTED
TSX
Hemostemix Wins Arbitration Decision
News Preview
Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that it was entered into...
Themefolio
Profiler
Peergroup
© Newsfile
23.01.2023
HEM
LISTED
TSX
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
News Preview
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is hiring four new biotechnologists to re-establish the Company's production of ACP-01 in Montreal. The Company is hiring an experienced autologous stem cell therapy Manufacturing M...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2023
HEM
LISTED
TSX
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
News Preview
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will fund $250,00...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2022
HEM
LISTED
TSX
Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
News Preview
Calgary, Alberta--(Newsfile Corp. - December 8, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus, issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Y...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2022
HEM
LISTED
TSX
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
News Preview
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") thanks Mr. Neim Malo, founder of Beefstro's, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).Cannot view this video? Visit:https://www.youtube.com/watch?...
Themefolio
Profiler
Peergroup
© Newsfile
17.11.2022
HEM
LISTED
TSX
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
News Preview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.Cannot view this video? Vis...
Themefolio
Profiler
Peergroup
© Newsfile
15.11.2022
HEM
LISTED
TSX
Hemostemix Announces Advancements in Its Automation of Production
News Preview
Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic...
Themefolio
Profiler
Peergroup
© Newsfile
26.10.2022
HEM
LISTED
TSX
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
News Preview
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductio...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2022
HEM
LISTED
TSX
Hemostemix Announces Presentation to the Emerging Growth Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference on Wednesday, October 26th at 12:00 EDT. At...
Themefolio
Profiler
Peergroup
© Newsfile
19.10.2022
HEM
LISTED
TSX
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
News Preview
Calgary, Alberta--(Newsfile Corp. - October 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.'s study of NCP-01.The spinal cord injury repair study will focus on the improvement of motor funct...
Themefolio
Profiler
Peergroup
© Newsfile
04.10.2022
HEM
LISTED
TSX
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
News Preview
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Fina...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
News Preview
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board.Dr. von Schwarz is a US based world renowned, triple board certified clinical an...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
News Preview
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board.Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
News Preview
Calgary, Alberta--(Newsfile Corp. - September 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board. Dr. Giannetti received her Medical Degree from McGill University. After training in cardiolo...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
News Preview
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board.Since 2019, Dr. Johannes Grillari is the director of the Ludwig Boltzmann Institute for Traumatology (LBI Trauma) -...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
News Preview
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board.Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Tr...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2022
HEM
LISTED
TSX
Hemostemix Announces Its Presentation to the Emerging Growth Conference
News Preview
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") invites individuals, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at 12:00 ET today https://goto...
Themefolio
Profiler
Peergroup
© Newsfile
13.09.2022
HEM
LISTED
TSX
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
News Preview
Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc. Mr. Abraham has more than 25 years of financing, business development, and governance and risk management experience in a bro...
Themefolio
Profiler
Peergroup
© Newsfile
31.08.2022
HEM
LISTED
TSX
Hemostemix Announces A Clarification
News Preview
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") received numerous enquiries about the press release of August 30, 2022. This press release details the results in a table format and clarifies a misprint.Table 1 is a summary of the patients that underwent a...
Themefolio
Profiler
Peergroup
© Newsfile
30.08.2022
HEM
LISTED
TSX
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
News Preview
Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the results of its Phase II Clinical Trial and the results of a new retrospective study of patients that underwent a trans-catheter, intramyocardial injection of angiogenic cell pr...
Themefolio
Profiler
Peergroup
© Newsfile
22.08.2022
HEM
LISTED
TSX
Hemostemix Announces Closing of UNIT Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - August 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a tranche of its previously announced non-brokered private placement of units ("Units") as announced on August 19, 2022 for gross proceeds of $192,000 (the "Offering"). The Offering consisted...
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2022
HEM
LISTED
TSX
Hemostemix Announces Unit Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - August 19, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to five Million Units priced at $0.30 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Sha...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2022
HEM
LISTED
TSX
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - August 12, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a second tranche of its previously announced non-brokered private placement of units ("Units") as announced on May 19, 2022 for gross proceeds of $1,364,710.10 (the "Offering"...
Themefolio
Profiler
Peergroup
© Newsfile
22.06.2022
HEM
LISTED
TSX
Hemostemix Announces Closing of UNIT Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - June 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it closed the first tranche of its non-brokered private placement of units ("Units") announced on May 19, 2022, for gross proceeds of $690,388.80 (the "Offering"). The Offering consisted of the issu...
Themefolio
Profiler
Peergroup
© Newsfile
14.06.2022
HEM
LISTED
TSX
Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
News Preview
Calgary, Alberta--(Newsfile Corp. - June 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has incorporated PreCerv Inc. ("PreCerv"), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to NCP-01 and its autologous stem cell technologies, to t...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
